Insilico Medicine Releases Positive Profit Alert for the First Half of 2026

About this update from Insilico Medicine Cayman Topco

CAMBRIDGE, Mass., July 8, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" or the "Company", HKEX: 3696), a generative artificial intelligence (AI)-driven clinical-stage biotech company, today delivered a positive profit alert for the six months ended June 30, 2026 ("First Half of 2026"). The strong financial performance was primarily propelled by sustained revenue growth alongside systematic improvements of operational efficiency. Insilico is expected to record a revenue in the range of approximately USD102.5 million to approximately USD106.5 million for the First Half of 2026, representing a year-on-year increase of approximately 272.7% to 287.3%. Net profit is expected to be in the range of approximately USD33.5 million to approximately USD39.5 million for the First Half of 2026, while adjusted non-IFRS net profit in the range of approximately USD45.5 million to approximately USD51.5 million for the First Half of 2026. Alex Zhavoronkov, PhD, Founder, Chairman, Co-CEO and CBO of Insilico Medicine, said: "Since the beginning of 2026, we have achieved a number of collaborations, which have provided strong momentum for our business growth. Today, Insilico operates in parallel as a leading AI platform, a cutting-edge automated science laboratory, and an efficiently innovation-driven biotechnology company, with multiple assets in clinical and late-stage preclinical development. We look forward to achieving sustained profitability." Global Collaborations Drive Business Growth The strong increase in financial performance was driven by the Company's achievements in advancing global out-licensing, co-development, and research collaboration in the First Half of 2026. During the period, Insilico announced multiple out-licensing and drug discovery collaborations with global partners including Servier, Hygtia Therapeutics, Qilu Pharmaceutical, CMS, Tenacia, Eli Lilly, and SK Biopharmaceuticals. The continuous forging of major collaborations not only validates the proven capabilities of Insilico's AI platform in empowering the global biopharmaceutical industry, but also serves as a powerful engine driving the Company's revenue growth. Beyond securing new strategic transactions, the Company successfully unlocked multiple milestones within its existing partnerships, bolstering both the predictability of its revenue and the resilience of its long-term allian...

View stock analysis, news, and events for Insilico Medicine Cayman Topco